You are here
Phase III Study Initiated for Bromfenac in Ocular Inflammation
"Following initiation of the Phase III study, bromfenac will become ISTA's third product candidate in Phase III or beyond, a significant milestone for any specialty pharmaceutical firm," stated Vicente Anido, Jr., Ph.D., ISTA's Chief Executive Officer. "Based on the anticipated progress of the Phase III clinicals, we would expect to complete testing in late 2003. This timeline could allow us to launch bromfenac as early as 2005, assuming successful completion of our Phase III efforts and timely submission and approval by the FDA of our New Drug Application (NDA) for bromfenac."